ReviewHuman vaccines & immunotherapeutics2013
Epidemiology of tick-borne encephalitis (TBE) in Europe and its prevention by available vaccines.
Review in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 189 citations in OpenAlex.
- Systematic Review and Meta-analysis of Foodborne Tick-Borne Encephalitis, Europe, 1980-2021.Emerging infectious diseases · 2022Pooled it
- Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2014Pooled it
- Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-centre, randomized controlled pilot trial.Journal of travel medicine · 2024Trial
- Type I and III interferon responses restrict infection by tick-borne orthoflaviviruses through IFI6.Journal of virology · 2026Article
- Current Knowledge on Tick-Borne Encephalitis Virus Interaction with Ticks: Acquisition, Dissemination, and Persistence.Pathogens (Basel, Switzerland) · 2026Review
- Epidemiology of tick-borne diseases diagnosed in patients in north-eastern Italy, 2015-2022.BMC infectious diseases · 2026Observational
- High diversity and distribution of ticks and tick-borne diseases in Sudan emphasizes the need for implementing cost-effective community One Health strategy.Frontiers in microbiology · 2026Review
- Tick-Borne Encephalitis in the 21Le infezioni in medicina · 2026Review
- Three-dimensional mapping of tick-borne encephalitis virus distribution in the mouse brain using a newly engineered TurboGFP reporter virus.Emerging microbes & infections · 2025Article
- Sex-dependent impairment of antibody responses to tick-borne encephalitis virus vaccination and infection in obese mice.The Journal of general virology · 2025Article
- Article
- Mature dengue virus particles inactivated by a non-ionic detergent retain quaternary neutralizing epitopes and induce potent neutralizing antibodies.Frontiers in immunology · 2025Article
- Tick-Borne Encephalitis Virus Infection in a Two-Year-Old Child Returning from Switzerland (July-August 2023): Is It Time for TBE Immunization of Serbian Travelers?Pathogens (Basel, Switzerland) · 2024Article
- What makes patients tick? Vaccine preferences against tick-borne encephalitis in four European countries.BMC infectious diseases · 2024Article
- Transcriptional Response to Tick-Borne Flavivirus Infection in Neurons, Astrocytes and Microglia In Vivo and In Vitro.Viruses · 2024Article
- Co-infection dynamics ofInfection and immunity · 2024Article
- Global Seroprevalence of Tick-Borne Encephalitis Antibodies in Humans, 1956-2022: A Literature Review and Meta-Analysis.Vaccines · 2024Review
- An Update on the Entomology, Virology, Pathogenesis, and Epidemiology Status of West Nile and Dengue Viruses in Europe (2018-2023).Tropical medicine and infectious disease · 2024Review
- Tick-borne zoonotic flaviviruses andOne health (Amsterdam, Netherlands) · 2024Review
- Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick-borne Encephalitis (TBE), which is caused by a Flavivirus, is the most common tick-transmitted disease in Central and Eastern Europe and Russia. Today, TBE is endemic in 27 European countries, and has become an international public health problem. The epidemiology of TBE is changing owing to various factors, such as improvements in diagnosis and case reporting, increased recreational activities in areas populated by ticks, and changes in climatic conditions affecting tick habitats. Vaccination remains the most effective protective measure against TBE for people living in risk zones, occupationally exposed subjects and travelers to endemic areas. The vaccines currently in use are FSME-Immun(®), Encepur(®), EnceVir(®) and TBE vaccine Moscow(®). The numerous studies performed on the efficacy and safety of these vaccines have shown a high level of immunogenicity and an excellent safety profile. Several studies have also shown a high level of cross-protection among strains belonging to different subtypes. In the present paper we attempted to describe the continuously changing epidemiology of TBE in European States and to overview clinical development of available vaccines paying particular attention on cross-protection elicited by the vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.